These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35499185)

  • 21. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
    Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
    J Am Acad Dermatol; 2023 Jan; 88(1):29-39. PubMed ID: 35820547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
    Merola JF; Parish LC; Guenther L; Lynde C; Lacour JP; Staubach P; Cheng S; Paris M; Picard H; Deignan C; Jardon S; Chen M; Papp KA
    J Am Acad Dermatol; 2024 Mar; 90(3):485-493. PubMed ID: 37852306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
    Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
    Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
    Stein Gold L; Papp K; Pariser D; Green L; Bhatia N; Sofen H; Albrecht L; Gooderham M; Chen M; Paris M; Wang Y; Callis Duffin K
    J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
    J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apremilast for psoriasis treatment.
    Carrascosa JM; Del-Alcazar E
    G Ital Dermatol Venereol; 2020 Aug; 155(4):421-433. PubMed ID: 32545946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis.
    Ivanic MG; Thatiparthi A; Walia S; Liao W; Wu JJ
    J Drugs Dermatol; 2021 Aug; 20(8):837-843. PubMed ID: 34397197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).
    Papp KA; Beyska-Rizova S; Gantcheva ML; Slavcheva Simeonova E; Brezoev P; Celic M; Groppa L; Blicharski T; Selmanagic A; Kalicka-Dudzik M; Calin CA; Trailovic N; Ramon M; Bareket-Samish A; Harpaz Z; Farbstein M; Silverman MH; Fishman P;
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):1112-1120. PubMed ID: 38279575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
    Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
    Gottlieb AB; Strober B; Krueger JG; Rohane P; Zeldis JB; Hu CC; Kipnis C
    Curr Med Res Opin; 2008 May; 24(5):1529-38. PubMed ID: 18419879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Qiu J; Liu J; Liu W; Lin F; Shi N
    Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.